about
Is There a Role for Genomics in the Management of Hypertension?A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue.Understanding primary aldosteronism: impact of next generation sequencing and expression profiling.Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas.Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells.a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III.Confirmatory tests in the diagnosis of primary aldosteronism.Primary aldosteronism: who should be screened?Diagnosis and treatment of unilateral forms of primary aldosteronism.Issues in the Diagnosis and Treatment of Primary Aldosteronism.Renin and aldosterone measurements in the management of arterial hypertension.Subtype Diagnosis of Primary Aldosteronism: Approach to Different Clinical Scenarios.Hyperaldosteronism: How to Discriminate Among Different Disease Forms?Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.Familial hyperaldosteronism type III.Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis.Aldosterone does not modify gene expression in human endothelial cells.Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro.Association Between Lifestyle and Systemic Arterial Hypertension in Young Adults: A National, Survey-Based, Cross-Sectional Study.Long-term cardio- and cerebrovascular events in patients with primary aldosteronism.ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions.The SPARTACUS Trial: Controversies and Unresolved Issues.GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism.Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients.Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma.Liddle Syndrome: Review of the Literature and Description of a New Case.Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy.Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism.Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas.Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients.Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study.Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism.KCNJ5 Mutations in European Families With Nonglucocorticoid Remediable Familial HyperaldosteronismHigh-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damageRapid cortisol assay increases the success of adrenal vein sampling18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypesDiagnosis and treatment of primary aldosteronismEffect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism
P50
Q33838442-4A1A53EE-3582-40C3-8E2A-E986F1804508Q34810955-D89EB616-2DE4-4834-8DEF-25BF72346C83Q34850075-DAF7E134-743F-41A4-8D1B-398908A2B582Q35760982-F6EE37E0-6DB6-4229-BBBC-38951C502959Q36134732-9E3D7F9D-6FB3-444A-8E0F-2EEDAB1D4741Q37275979-48E3B4E4-B850-4453-A145-1F4AAE3362A2Q37684880-3D1E34E7-1666-4AF2-93DC-9DE24CFF0FB6Q37961470-7210414A-4519-455E-9411-CCCD5524C132Q38131026-CF8707B3-3538-41AC-8880-6F27C7FAD508Q38411728-38D47FB5-B60C-462C-8717-F7A924F1C0ECQ38494051-175E2718-52E4-41FD-B7F6-3D7E87DF3CB1Q38635345-555F08BA-D890-464E-84F9-EB92881FFC9CQ38823256-AA46E1F4-A328-4EE2-BE0E-6BCA93241D8FQ38831779-35BEDDA3-3126-4E29-AE74-991ED09CC875Q38849463-F4B98792-1A1A-4599-B5F2-24B45DC3FD2BQ39266522-1AE2A543-7215-4362-A370-6A903C1D69F2Q39397022-96A2984C-7C15-48A0-A51A-F890A64E7A5FQ39446158-50CD2FDC-7EB9-40AC-A136-B5D4C6AEB75AQ39715556-66481A63-F87D-4B7D-9BD3-1B808DE961E6Q40891169-C2540CD0-6952-4C06-816D-A456B0D2E5FAQ45144064-E510E4EA-A709-4EEF-B4F8-E7599D3D4E01Q46722939-CE1F6DD8-EF3C-4DBE-80A4-F81DECB86D0AQ47600152-A1F314A8-EEDB-403E-908B-ABE84B617418Q47710679-5577ABDA-A381-4865-8EBF-C837F78D3059Q50054850-7E38678C-3EFC-4756-93EB-868A6ABA0C2DQ50751723-17D8AFB2-6AD4-4316-BF5B-FD91DB95441AQ51138106-5CB5DF2D-56E2-4BFC-AC26-8955824D732BQ52657742-88A6C665-57AD-4751-9F00-D64F4D05F657Q52874608-5C8A345D-7D02-44BA-8D7C-4C4632ED66C0Q52988479-EFC58031-DA61-4FE4-9CF2-E49AB7AFC619Q53088386-2DFA5573-7728-4816-B23D-443B103EB6B2Q53183212-64E1C569-8EE9-452B-A183-E5D5A202AAB9Q53216236-CC3E0E42-DFAF-445F-8A2E-F373A67A1695Q54327400-ABAD14AB-1CA3-4425-85C8-01D34B580C77Q56964322-C8491BC7-4B69-49C1-BE26-D119E6AFBD95Q82254253-260F5DEE-6247-48D7-92E1-4FBCB499EDE3Q82504721-0CA46DAE-46E6-4560-AB99-CCC2CF499C91Q83216131-088799C9-0DEB-4C9D-9390-A28B3EF00876Q83327423-0F3A7B05-4666-4809-A96C-A3BC91C27B85Q83438076-1A8DE7E9-7306-400A-9A2E-E0FC52FBAE3D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Silvia Monticone
@ast
Silvia Monticone
@en
Silvia Monticone
@es
Silvia Monticone
@nl
type
label
Silvia Monticone
@ast
Silvia Monticone
@en
Silvia Monticone
@es
Silvia Monticone
@nl
altLabel
Silvia MONTICONE
@en
prefLabel
Silvia Monticone
@ast
Silvia Monticone
@en
Silvia Monticone
@es
Silvia Monticone
@nl
P106
P1153
19337673900
P21
P31
P496
0000-0002-7322-2005